

Title

Renal Cell Carcinoma / Melanoma Treatments

Reference Number: RDF2339-24

Date of Response: 05/03/24

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Q1. How many patients have been treated in the past 3 months with the following agents for renal cell carcinoma (any stage):

Treatment	Count
Avelumab + Axitinib	7
Axitinib	*<5
Cabozantinib	17
Everolimus	*<5
Lenvatinib + Everolimus	0
Nivolumab monotherapy	19
Nivolumab + Cabozantinib	0
Nivolumab + Ipilimumab	*<5
Pazopanib	*<5
Pembrolizumab monotherapy	8
Pembrolizumab + Lenvatinib	9
Pembrolizumab + Axitinib	0
Radiotherapy only	*<5
Sunitinib	*<5
Temsirolimus	0
Tivozanib	0
Other active systemic anti-cancer therapy	0
Palliative care only	8

Q2. How many patients have been treated in the past 3 months with the following agents for melanoma (any stage) :

Treatment	Count
Cobimetinib	0
Dabrafenib	*<5
Dabrafenib + Trametinib	13
Dacarbazine	0
Denosumab	0
Encorafenib + Binimetinib	10
Ipilimumab monotherapy	*<5
Ipilimumab + Nivolumab	19
Nivolumab monotherapy	16
Nivolumab + Relatlimab	0
Pembrolizumab	77
Trametinib	0

Vemurafenib	0
Vemurafenib + Cobimetinib	0
Other active systemic anti-cancer therapy	13
Palliative care only	*<5

Q3. Does you trust participate in any clinical trials for the treatment of melanoma? If so please provide the name of each trial and number of patients that are taking part? Thank you for your help.

Answer: We are currently participating in 3 clinical trials for melanoma:

Trial	Total patients
DANTE	*<5 Recruits
Fianlimab + Cemiplimab Versus Pembrolizumab In Patients With Completely Resected High-Risk melanoma	0
COMBI-AD	*<5 Recruits

*<5 - Section 40 (2)

Please note that in accordance with Section 40 (2) where activity is 5 or less than 5, the Trust is unable to provide the exact information. We consider the data exempt on the following grounds:

The Trust considers that disclosure of the information risks identifying individuals. The reason for this is that the number of patients for which this applies is very low. This and the fact that the data requested relates to the RDUH Health NHS Trust only and therefore relates to patients treated in a specific location (rather than covering a larger geographical area), increases the risk of identification or self-identification. The Trust's view is that s.40(2) is applicable because disclosure of information which could lead to a patient being identified would be a breach of the patient's rights under the Data Protection Act Data Protection Principles set out in Schedule 1 of the GDPR, namely Principle 1.